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The advent of effective combination antiretroviral therapy (ART) in
1996 resulted in fewer patients experiencing clinical events, so that
some prognostic analyses of individual cohort studies of human
immunodeficiency virus-infected individuals had low statistical
power. Because of this, the Antiretroviral Therapy Cohort
Collaboration (ART-CC) of HIV cohort studies in Europe and
North America was established in 2000, with the aim of studying
the prognosis for clinical events in acquired immune deficiency
syndrome (AIDS) and the mortality of adult patients treated for
HIV-1 infection. In 2002, the ART-CC collected data on more than
12,000 patients in 13 cohorts who had begun combination ART
between 1995 and 2001. Subsequent updates took place in 2004,
2006, 2008, and 2010. The ART-CC data base now includes data on
more than 70 000 patients participating in 19 cohorts who began
treatment before the end of 2009. Data are collected on patient
demographics (e.g. sex, age, assumed transmission group, race/eth-
nicity, geographical origin), HIV biomarkers (e.g. CD4 cell count,
plasma viral load of HIV-1), ART regimen, dates and types of AIDS
events, and dates and causes of death. In recent years, additional
data on co-infections such as hepatitis C; risk factors such as smok-
ing, alcohol and drug use; non-HIV biomarkers such as haemoglo-
bin and liver enzymes; and adherence to ART have been collected
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whenever available. The data remain the property of the contribut-
ing cohorts, whose representatives manage the ART-CC via the
steering committee of the Collaboration. External collaboration is
welcomed. Details of contacts are given on the ART-CC website
(www.art-cohort-collaboration.org).
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Why was the cohort set up?
The Antiretroviral Therapy Cohort Collaboration
(ART-CC) was established in 2000 to study the prog-
nosis for adult patients treated for human immuno-
deficiency virus-1 (HIV-1) infection in Europe and
North America. The widespread use since 1996 of
combination antiretroviral therapy (ART) has sub-
stantially improved the prognosis for HIV-positive pa-
tients as compared with those treated with previously
available drug regimens of nucleoside reverse tran-
scriptase inhibitors (NRTIs), either in the form of
monotherapy with zidovudine or as dual therapy
with a second NRTI.1
The substantial reductions in the number of events
and deaths related to acquired immune deficiency syn-
drome (AIDS) following the introduction of combin-
ation ART meant that modelling of prognosis among
different patient groups and according to different
prognostic factors often required larger numbers of pa-
tients than were available in individual cohorts at that
time. Therefore, the important task of defining progno-
sis and prognostic factors in the era of combination
ART required several cohorts to contribute data to a
collaborative data base. The prognosis for patients
starting treatment with combination ART, defined as
a combination of at least three drugs belonging to two
different classes of drugs, depends on their prior ex-
posure to NRTI monotherapy or dual therapy, because
the development of resistance to NRTI drugs as a result
of incomplete viral suppression meant that ‘treat-
ment-naive’ patients who had not previously been
treated when they began triple ART had a better prog-
nosis. Because future patients would begin treatment
with triple ART rather than with NRTIs, treating phys-
icians and their patients needed to know the prognosis
for treatment-naı¨ve patients starting combination ART
according to their demographic characteristics, disease
stage, and treatment options. The ART-CC was able to
address this key clinical question and thereby improve
care for HIV-positive patients.
The co-ordinating centre of the ART-CC was estab-
lished in the Department of Social Medicine (now the
School of Social and Community Medicine) of the
University of Bristol, UK. An annual international
workshop for researchers working with observational
cohorts of HIV-positive patients had been set up in
1997, under the sponsorship of the pharmaceutical
company GlaxoSmithKline. At the fourth such
workshop, held in 2000 in Marbella, 16 cohorts, in
Europe and North America, were approached, and 13
agreed to participate in the collaboration. The ART-CC
Steering Committee consists of the Principal Investiga-
tor, a representative from each cohort, the
co-ordinating team and representatives of patient
groups. GlaxoSmithKline funded the first 6 months
of the study, and it has since been funded by the
UK Medical Research Council together with the fund
providers for the contributing cohorts (see Appendix).
The aim of the ART-CC, as specified in its detailed
Principles of Collaboration, is ‘to examine the progno-
sis of HIV-infected, antiretroviral drug-naı¨ve patients
starting combination ART, with a focus on questions
that cannot be fully addressed in analyses of data
from individual cohorts. In particular, analyses will
focus on prognosis of major clinical events (particularly
AIDS, AIDS-defining conditions, and all-cause and
cause-specific mortality).’
Which cohorts contribute to the
collaboration?
The ART-CC is a collaboration of HIV cohort studies
in Europe and North America. Table 1 lists the co-
horts that have contributed data to the ART-CC.
Prospective cohort studies are eligible to participate
if they have enrolled at least 100 HIV-1–positive pa-
tients aged 16 years or older who have not previously
received antiretroviral treatment, who began ART
with a combination of at least three antiretroviral
drugs after 1996, and who have been followed for a
median of at least 1 year after the initiation of ART.
Patients are eligible only if they have had at least one
measurement of their CD4 cell count and plasma viral
load of HIV-1 RNA within 3 months before starting
ART. All cohorts have been approved by local ethics
committees or institutional review boards, use stan-
dardised methods of data collection, and schedule
follow-up visits at least once every 6 months for
their patients.
Who are the participants in the
cohorts?
Each cohort in the ART-CC recruits patients in differ-
ent ways, and the cohorts therefore differ in how
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representative they are of their local HIV-positive and
treated populations. Only a few cohorts, such as the
Swiss HIV Cohort Study (SHCS), estimate the rate of
response to requests for participation. For example,
the ANRS CO4 French Hospital Database on HIV
(FHDH), together with the ANRS C03 Aquitaine
Cohort, are likely to be fairly representative of the
French HIV-positive population in whom a diagnosis
has been made and who are in care. However, the
Veterans Aging Cohort Study (VACS) includes only
veterans of the US armed forces and is therefore not
representative of the HIV-positive population of the
US. Table 1 provides details of the cohorts in the
ART-CC, including the ways in which their patients
are recruited and whether they consider their partici-
pants to be representative of HIV positive people in
their region or country. A strength of the ART-CC is
that most participating cohorts recruit patients who
are in usual clinical care for HIV infection in a par-
ticular geographic setting, as opposed to subjects spe-
cifically recruited for the purpose of an
epidemiological study, such as a randomised con-
trolled trial. Figures 1 and 2 show maps indicating
the sites of cohorts that contribute to the ART-CC.
How often has the database been
updated?
The ART-CC database is updated approximately every
2 years. A protocol is written for the data extraction
for each update; it specifies names and descriptions
of variables collected, eligibility criteria, and coding
tables for opportunistic infections and antiretroviral
drugs. The ART-CC data base has used the HIV
Cohorts Data Exchange Protocol (HICDEP: www.
hicdep.org) since 2008. The first ART-CC database
was compiled in 2001 and included 13 cohorts that
contributed information on 12 574 patients. In 2004
the update collected longer follow-up data on existing
patients as well as data on new patients who had
started treatment in more recent years. Table 2 pro-
vides further information about updates in 2006,
2008, and 2010, including the number of cohorts
and patients in each data set. The 2012 update is cur-
rently under way.
What has been measured?
The variables collected at each update of the ART-CC
data set have become more extensive over the years
and are listed in Table 2. The first data set included
only basic demographic, laboratory, and clinical vari-
ables at the beginning of a patients ART and at 6
months after the beginning of ART. In contrast, the
most recent update collected comprehensive longitu-
dinal data for laboratory values (including both prog-
nostic markers in HIV infection such as CD4 cells and
viral load, and non-HIV–specific biomarkers such as
haemoglobin and creatinine), start and stop dates of
antiretroviral drugs used during the observation
period and the reasons for changes in a drug regimen,
and data on causes of death. A panel of experts has
retrospectively validated causes of death in ART-CC,
using the CoDe system (http://www.cphiv.dk/CoDe/
tabid/55/Default.aspx).2
Figure 1 Map of North American cohorts in the Antiretroviral Therapy Cohort Collaboration
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Table 3 shows baseline characteristics of patients in
each of the 19 ART-CC cohorts that supplied data for
the 2010 update. The ANRS C04 FHDH cohort, which
recruits patients from most regions of France, contrib-
utes the largest number of patients. The cohorts are
heterogeneous in nature and outcomes.3 Reported
percentages of patients who have died vary from
1.4% in the Frankfurt cohort to 19% in the HOMER
cohort, which recruited a large number of injection-
drug users (IDUs). The proportion of female partici-
pants also varies greatly among cohorts, from 1.6% in
HAVACS (a cohort of US military veterans) to 33% in
FHDH (which has a large proportion of immigrants
from sub-Saharan Africa).
What is the extent of attrition?
Overall rates of loss to follow-up in the different
AST-CC cohorts has ranged from 2%–18%, depending
on opportunities for access to care outside the contri-
buting centres, and cohorts’ ability to track patient
transfers and pursue patients who miss appointments.
Thus, for example, losses to follow-up in the Royal
Free cohort are partly due to patients’ attending al-
ternative clinics in London. In France, IDUs and im-
migrants, and patients with lower CD4 cell counts
and higher viral loads, were more likely to be lost to
follow-up. In contrast, patients in Switzerland with
higher CD4 cell counts were more likely to be lost
to follow up.
What are the major findings
to date?
Prognosis from the beginning of
antiretroviral therapy and after
accounting for response to therapy
Our first paper on the prognosis for HIV-1–infected
patients from beginning of ART was published in
2002.4 This and several other papers from the
ART-CC have been cited in treatment guidelines.5–7
We showed that the CD4 cell count at which individ-
uals began ART strongly predicted disease progres-
sion. A higher viral load, older age, infection via
injection-drug use, and a diagnosis of AIDS before
the initiation of treatment were also predictors of
poorer outcome. The probability of death within 3
years after the beginning of treatment ranged from
0.8%–43%, depending on these risk factors. The prog-
nostic modelling methodology8 has been used by sev-
eral other collaborations,9.10 and the ART-CC
prognostic model has been validated with data from
the CASCADE collaboration.11 Further work examined
the way in which prognosis depends on the initial
response to ART.12 Viral load and CD4 cell count at
6 months strongly predicted subsequent survival,
whereas the values measured at the beginning of
treatment no longer predicted survival after account-
ing for the 6 month measurements.
Analyses were updated in 2007 to include new
patients who began ART up to 2003 and a longer
Figure 2 Map of European cohorts in the Antiretroviral Therapy Cohort Collaboration
EuroSIDA covers 31 European countries plus Israel and Argentina; the Infeccio´n por HIV y SIDA (PISCIS) Cohort includes
two regions: Catalonia and the Balearic Islands
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follow-up of existing patients in the ART-CC data-
base.13 Cumulative probabilities of AIDS and death
at up to 5 years from the beginning of ART were
provided in the paper that described the update13
and as an interactive risk calculator on the ART-CC
website (www.bris.ac.uk/art-cc/research/calculator/).
We investigated, in patients treated for at least 3
years, the prognostic importance, for AIDS and
death, of the CD4 cell count and HIV-1 viral load
measured at the beginning of ART and at 6 and 36
months later.14 Although the most recent values of
the CD4 cell count and viral load are the most im-
portant prognostic factors, changes in the CD4 cell
count from 6 to 36 months after the beginning of
ART, and the value of the viral load at 6 months,
were also prognostic for AIDS.
We showed that the incidence of all AIDS-defining
events decreased substantially after the beginning of
ART, and that the decline was most pronounced for
events with a viral aetiology.15 We found that some
patient groups, such as men who have sex with men,
experience a greater benefit from ART than do other
groups,16 and that AIDS-related events differed in
their importance for subsequent prognosis.17 In later
updates data were collected on non-HIV biomarkers,
for example, haemoglobin, liver enzymes and creatin-
ine, and were incorporated into prognostic models.18
Trends in mortality over time, life
expectancy and cause-specific mortality
In 2006, after a decade of availability of combination
ART, we reported on trends over time in the response
to treatment for HIV and the prognosis for treated pa-
tients.19 Standardised mortality rates in HIV-positive
individuals were compared with those in country-
matched background populations.20 Estimates of life
expectancy were shown to have increased by some
13 years for patients in whom ART was begun from
2003–2005 as compared with 1996–1999, with an ac-
companying decline in mortality of nearly 40% in the
same period.21 However, life expectancy in these pa-
tients remained well short of that of the general popu-
lation, and patients treated later in the course of their
infection had a shorter life expectancy.
Table 2 Measurements collected at each data update in the Antiretroviral Therapy Cohort Collaboration
Update Cohorts N Patients N Data collected
2001 13 12 574 Demographic variables: age, sex, risk factors for transmission
Laboratory variables: CD4 cell counts and viral loads at start of ART and at 6 months
Clinical variables: ART start date, ART drug regimen at baseline, CDC disease stage
at start of ART
Outcome variables: AIDS events, last visit date, death, death date
2004 12 22 217 As above
2006 15 49 040 As above, plus: Demographic variables: Race/ethnicity, geographical origin based on
country of birth, nationality
Laboratory variables: CD4 cell count closest to event/death and last count during
treatment, with dates. At least one 3-year measurement of each prognostic vari-
able (CD4 cell count, HIV-1 RNA plasma viral load, haemoglobin), with dates and
an indicator variable for being on/off treatment, and whether patient experienced
virological failure (defined as an a viral load of4500 during treatment) after 6
months and within 3 years of initiating treatment
Clinical variables: Total number of ART drugs and classes to which patient was
exposed at 3 years, whether patient has changed treatment from initial regimen,
as ascertained when available
Outcome variables: Causes of death, loss to follow-up indicator, and reason for loss
to follow-up
2008a 18 59 483 As above, plus:
Demographic variables: current alcohol, injection-drug use and smoking
Laboratory variables: longitudinal measurements of CD4 cells and viral load are now
available, as well as other longitudinal laboratory measures (such as alanine
aminotransferase, creatinine) and virology measures (such HCV/HBV status)
Clinical variables: Detailed information about start/stop dates of drugs and reasons
for drug changes.
2010 19 74 048 As above
aData were collected according to the HICDEP (see http://hicdep.org) format from the 2008 update onwards. This enabled collection
of longitudinal data.
Abbreviations: ANRS, Agence Nationale de Recherche SIDA; ART, antiretroviral therapy; CDC, US Centers for Disease Control and
Prevention; HBV, hepatitis B virus; HCV, hepatitis C virus; IDU, injection-drug user.
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From 2006 onward, we collected and classified infor-
mation about causes of death. Overall, almost 50% of
deaths were caused by AIDS.2 Because rates of death
from AIDS declined with the duration of ART, rates of
non-AIDS–related death exceeded those of death from
AIDS after 4 years of ART. Lifestyle-related causes of
death such as suicide, drug overdose, and liver diseases
(mainly hepatitis) were the most frequent causes of
non-AIDS–related deaths, with the most common
non-AIDS–related cancer being lung cancer. Deaths
from causes associated with ageing, such as cancers
other than lung cancer and cardiovascular disease,
will be of increasing importance in treated
HIV-positive people over the next decade, and the
ART-CC will have the capacity to explore these trends.
When to begin antiretroviral therapy
The CD4 cell count below which ART should be begun
remains a central issue in the care of HIV-positive
individuals. In 2009 we attempted to address this
question by combining data from observational
cohort studies conducted before and after the era of
combination ART,22 and concluded that deferring
treatment until the CD4 cell count was under 350
cells/ml was associated with increased rates of AIDS.
International treatment guidelines were amended
later in 2009 to account for our own and others’ find-
ings, mainly in cohort studies. However only a rando-
mised controlled trial will definitively show whether
deferring treatment on the basis of the CD4 cell count
will increase the rates of AIDS. Results of the
Strategic Timing of Antiretroviral therapy (START)
trial23 are awaited with interest in this regard.
Prognosis for patients infected through
injection-drug use
Patients infected with HIV-1 through injection-drug
use have worse outcomes after treatment than do
those infected sexually.24 We found that mortality
rates of IDUs were twice as high as those of non-
IDUs, and that IDUs experienced higher rates than
did non-users of infection drugs of almost all causes
of death, particularly liver-related deaths and deaths
from direct effects of substance abuse. The CD4 cell
count predicted death more strongly for non-users of
injection drugs than for IDUs, indicating that excess
mortality in IDUs was related to factors other than
HIV. Excess mortality in IDUs may also relate to
suboptimal management of HIV disease in these
individuals.
Estimated effects of different antiretroviral
drugs on the basis of observational studies
and clinical trials
We found evidence that rates of AIDS and death
varied according to the drugs included in the initial
ART regimen,19 and that between-regimen differences
in rates of short-term virological failure (the outcome
most commonly used in clinical trials) do not neces-
sarily translate to longer-term differences in rates of
various clinical outcomes.25 We compared the results
of two randomized trials done by the AIDS Clinical
Trial Group (ACTG 5095 and ACTG 5142) with those
estimated in ART-CC cohorts, which follow patients
in routine care.26 Results for the ART-CC cohorts were
comparable with those of the trials conducted in simi-
lar settings, and we concluded that the results of clin-
ical trials appear ro be generalisable to routine-care
settings in resource-rich countries.
Other topics covered by the Antiretroviral
Therapy Cohort Collaborative
Collaborative analyses have compared mortality
during the first year of ART in resource-limited and
high income settings.9 In the past, similar compari-
sons of the incidence of tuberculosis were
reported.27,28 Other questions addressed by the
ART-CC include the way in which the effect of prog-
nostic factors at the beginning of ART varies with the
duration of treatment,29 and the effect of baseline
CD4 cell counts on the clinical significance of
short-term immunologic responses to ART in individ-
uals with virologic suppression.30
Current work
We have recently examined the effect of sex,31 race/eth-
nicity, and geographical origin32,33 on the prognosis in
HIV infection and investigated the heterogeneity in mor-
tality rates among cohorts.3 Ongoing analyses are ad-
dressing the durability of first-line ART and the
cumulative incidence of and risk factors for different
types of changes in regimen and of the interruption of
ART. This work will be extended to use methods for
causal inference34 to examine the implications for sub-
sequent mortality of different strategies for switching
ART regimens after virological failure. As longer
follow-up data become available, we will estimate the
prognosis for patients treated for up to 10 years, investi-
gate whether the prognosis in HIV-1 infection becomes
stable after an initial response to ART, and investigate the
effect of cumulative viral load on specific causes of death.
We are also now investigating measures and effects of
adherence to ART. The ART-CC is working increasingly
closely with other collaborations of HIV cohort studies, in
particular the Collaboration of Observational HIV
Epidemiological Research Europe (COHERE), which
now merges the data for European cohorts participating
in the ART-CC, as well as the HIV-Cohorts Analyzed
Using Structural Approaches to Longitudinal Data
(HIV-CAUSAL) Collaboration, and the International epi-
demiologic Databases to Evaluate AIDS (IeDEA) South-
ern Africa Collaboration. The ART-CC also works with
the North American AIDS Cohort Collaboration on Re-
search and Design (NA-ACCORD), IeDEA West Africa,
and the Concerted Action on SeroConversion to AIDS
and Death in Europe (CASCADE) collaboration.
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What are the main strengths and
weaknesses?
The generosity and collaborative spirit of researchers
in the contributing cohort studies has been a key
strength of ART-CC, which has brought together re-
searchers with clinical, epidemiological and statistical
expertise. The ART-CC data base includes large num-
bers of patients enrolled in diverse cohorts from two
continents, so that the results for different cohorts are
likely to be generalisable to patients in clinical care in
this broad setting. All patients in the ART-CC were
ART-naı¨ve when they began treatment, and the re-
sults for the Collaboration are therefore relevant to
new patients starting combination ART. However,
prognostic models are fitted on historic data, and
therefore provide trailing indicators of prognosis for
new patients starting ART with improved drugs and
co-formulations. The large data set of the ART-CC
permits examination of prognoses for specific causes
of death, but these data are incomplete. So far, it has
been possible to classify only 85% of deaths, and there
will have been some misclassification because of limi-
tations of available data. There is likely to be some
under-ascertainment of deaths, which may result in
estimates of mortality rates and life expectancy being
over-optimistic. Nevertheless, most of the cohorts in
the ART-CC link to death registries, but at intervals
that vary from monthly to tri-annually.3 Because the
data are mainly collected as part of routine clinical
care, there are issues with the standardisation of def-
initions and completeness of data. Moreover, not all
laboratory, demographic and lifestyle measures are
available from all cohorts. Data on important life-style
risk factors, such as smoking and substance abuse,
which affect mortality and may be highly prevalent
in some HIV-positive populations, have not yet been
sufficiently widely available for inclusion in prognos-
tic models. Data on adherence to ART are now being
collected, but not data on patient physical and psy-
chological symptoms or quality of life measures.
Can I get the data gathered by the
Antiretroviral Therapy
Collaboration?
The data collected by the ART-CC remain the property of
the contributing cohorts, and all analyses of these data
must be approved by the ART-CC steering committee.
Each cohort has a representative on the steering com-
mittee, which also includes patient representatives who
provide guidance by asking research questions that are
important and relevant to patients. Interested investi-
gators should contact the co-ordinating centre and will
be asked to fill in a concept sheet which gives brief de-
tails of the proposed study. All concept sheets are dis-
cussed by the steering committee, and projects must
also be approved by contributing cohorts. We welcome
the addition of collaborating cohorts to the ART-CC;
eight cohorts have joined since the Collaboration was
established in 2000. More information, including details
of collaborating centres, is available on the ART-CC
website (www.art-cohort-collaboration.org).
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KEY MESSAGES
 Patients starting ART later in the course of their infection had worse prognosis, as did those infected
via injection drug use.
 Life expectancy of HIV positive individuals increased by 13 years for those initiating ART in 2003–05
compared with 1996-99.
 Overall, almost 50% of deaths were from AIDS, but rates of non-AIDS death exceeded rates of AIDS
death after four years of ART.
 Deferring treatment until CD4 count is less than 350 cells/mL was associated with increased rates of
AIDS.
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